µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ dsP|j(y
w)-@?jN
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ &fA`Od6l"
p
D!IB`cA4
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ
&T?>Kx
g~_cYy
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ~Nf01,F
{=
Dtajz
1. CD4 L%`~`3%n-
/km^
I
H
2. T cell receptor(TCR) ,>CFw-Nxu
\UFno$;mA
3. immunoglobulin superfamily (IgSF) )t={+^Xe
\&]M \
4. selectin 2%0zPflT
}xTTz,Oj$
5. anti-idiotypic antibody (¦ÁId) b?7?iV4
PETrMu<
6. major histocompatibility complex(MHC) F7J-@T<
I1U {t
7. immunotolerance S!8eY `C.
9 m&"x/k
8. biological reponse modifier(BRM) (:E_m|00;
W>eJGZ<
9. immune reponse gene (Ir gene) {Eb
R
=
6gwjrGje\
10. reshaped antibody (or reconstituted antibody) P,!si#
p3 I{
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© '-3A
WBWI1
W3*BdpTw
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ [P8Y
<&TAN L
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? Z `O.JE
Yo@>O98
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ 3;~1rw=$<
{YWj`K
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? Je2o('MA
S6,AY(V
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) \c>9f"jS_
CeS8I-,
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ m9ts&b+TE
K+Q81<X~
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? 3 8pw
?XL [[vyr
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? K@U"^
`G2
2_;.iH
6
¡¡ pSkP8'
?
/XS6X
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ QZef
=
x68J [; jm
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? xr?=gY3E;
UoPd>q4Uj
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? rtv\Pf|
^tsIgK^9H
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ T[U&Y`3g
Smo^/K`f9
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ~cy/\/oO
`GC7o DL
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ !vfjo[v
uljd)kLy4O
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© flIdL,
AOWX=`J8V
1. CD8 R!W!8rr3
0`"]mYH
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) 1""9+4
6xr$
3. immunoglobulin fold(Ig fold) '[I_Iu#,
)+wBS3BC
4. cadherin (Ca-dependent cell adhesion moleculers) YoGnk^$
QUb#;L@okn
5. idiotype-anti-idiotypic antibody immune network theory x?KgEcnw2X
;WJ}zjo >
6. HLA class II antigen x8.7])?w
*rSMD_>
7. complementarity-determining region (CDR) uT8/xNB!
n*CH,fih:
8. perforin(or pore-forming protein ,PFP) 8/U=~*`_
R3d>|`) +
9. high affinity IL-2 receptor O;ZU{VY
C 6Bh[:V&
10. artificial active immunization :1q+[T/ @
( u@[}!
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ,E3"AisI
\o?zL7
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠiUi{)xa2
N)lzX X
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 6%JKY+n^
mwZ
esSxB_
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ @SDsd^N{2P
/v:g'
#n
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ m}T^rX%m_
1HskY| X
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) =<_xUh.
] ^tor
1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ "L1cHP~d
SGZOfTcY
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? Z=sy~6m+v
ta> g:
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 9hHQWv7TgK
?O8NyCeb7
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 4-eb&
+h pXMO%?
¡¡ 6i(V+
d;|e7$F'
Vl{CD>$,
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ K7FuMB
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ hqnJ@N$yY
;DL|%-%;$r
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ DifRpj I-0
fGcAkEstT!
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 95_?F7}9
3I^KJ/)A
1. immunoglobulin gene rearrangement 4};!nYey!
AU}lKq7%
2. the common chain of cytokine receptor (or a cytokine receptor `4.Wdi-Si
q#pBlJ.LK
subunit shared by some cytokine receptors) >a%NC'~rc
]}<.Y[!S
3. flow cytometry(FCM) P|v ;'9
-DlKFN
4. carrier effect pco~Z{n
Y)N(uv6
5. positive selection of T lymphocytes in thymus +o?.<[>!GR
6]\F_Z41
6. mouse TH1(Th1) and TH2(Th2) subsets ,yWTkql
eE>3=1d]w
7. perforin (pore-forming protein ,PFP) ~4U[p 50
W:3u$LTf*f
8. ADCC(antibody-dependent cell-mediated cytotoxicity) 4adCMfP7.
la8se=^
9. SH-2(src-homology region 2) n8w|8[uV^
Ve2z= 6(
10. Ab2¦Â (internal image) 'P)xY-15
N$/{f2iC
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© $.QnM
1HN_
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? uz
` H
C@buewk
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? B+jT|Y'
E,xCfS)
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ{uM0J$P :
Uf
q"_^4
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ -v&Q'a
1ScfX\F=
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ~"gOq"y5p
YM 7P!8Gc
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) lDe9EJR
D?}LKs[
ÃâÒßѧרҵ£º XC?H
ZZ!d:1'7
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ >%qGK-_
bsr
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 5`^"<wNI
\z:p"eua z
´«È¾²¡Ñ§×¨Òµ£º *W(b = u
SQvicZAN)`
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ i/C#fIB2
klT6?'S
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ CS5
0wY
_]j=[|q 9
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ /iy2j8:z
ClaYy58v
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? +ywWQ|V
aFyN
m@a
ovm*,La)g
d>@{!c-
jd]MC*%
xqP0Z),Ow
-/#3U{O
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ J#Bz)WmR
aFIet55o
ÃâÒßѧÊÔÌâ fkRb;aIl
%m+Z rH(
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© SkvKzV.R;
qpp:h_E
1. Fas(CD95)/FasL 86R}G/>>e
eZ}FKg%2[
2. common chain of cytokine receptor %6Hn1'7+v
t:m
t9}$d
3 . TCR/CD3 complex e=8ccj
-[^wYr=
4. negaive selection of thymocytes ^,U&v;
;pAkdX&b